At a recent conference of American Society of Clinical Oncologists (ASCO) annual meeting, Duke University research group released news of a new vaccine containing common type of herpes virus, human cytomegalovirus (CMV).
Used in conjunction with the chemotherapy drug temozolomide, seems to be successful delaying the recurrence of glioblastoma in a small group of patients.
Researchers at Duke University built upon this knowledge by developing a CMV vaccine, testing it on nearly two dozen patients, where early results appeared promising, but continued research is still required.
A Duke news release on the study is available at http://www.dukehealth.org/HealthLibrary/News/10320. Geoff.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment